Johnson & Johnson has submitted its global health vaccine data to obtain permission for emergency use.
While the company indicated that the US Food and Drug Administration is currently evaluating its vaccine, it said, “Using our vaccine will be easier because it is from a single dose.”
And if it gets the green light from the US Food and Drug Administration, this vaccine will be the third authorized in the United States, after the Pfizer-Bionic and Moderna vaccines.
This vaccine is especially needed because it has two advantages that are logistically important, as it can be stored in normal refrigerant temperatures, which will greatly facilitate its distribution, and it is also given to people with only one dose.
Critical station
The FDA must now set up an advisory committee on vaccines that will provide an opinion after considering clinical trial data. It will be responsible for determining whether the benefits of the vaccine outweigh the risks of using it.
This step took about three weeks for the Pfizer / Bionic Moderna vaccine, but it may be faster this time. Then the green light for the vaccine will have to be given, possibly after the advisory committee gives its opinion.
66% effective
Johnson & Johnson pledged to ship 100 million doses of its vaccine to the United States before the end of June.
Corona Virus
–
–
The giant pharmaceutical company announced at the beginning of this month, the first results of its clinical trials that were conducted on about 44,000 people in eight countries.
The company said that the vaccine was effective in general by 66%, while the effectiveness increased to 85% in preventing severe symptoms of the virus.
A disturbing product
But these results also raised concern, as the vaccine was more effective in the United States (72%) than in South Africa (57%), as a mutated version of the virus appeared in this country and became the dominant one in it to a large extent.
Experts see this as an indication that any future mutated copies could end up bypassing the immune defenses developed by current vaccines. It is another reason, they think, to speed up vaccination campaigns.
– .
